Answers are grounded in this paper and cite their sources.
Experimental analysis reveals a significant rise in resistance levels in E. coli, suggesting mutations in mrdA can impact drug efficacy.
Durlobactam, a diazabicyclooctane β-lactamase inhibitor, exhibits direct antibacterial activity by binding to penicillin-binding protein 2 (PBP2). We generated a mutant strain of New Delhi metallo-β-lactamase-producing Escherichia coli with a durlobactam minimum inhibitory concentration of 2 µg/mL, representing a 16-fold increase from baseline, by exposing it to increasing concentrations of durlobactam. Resistance was attributed to a point mutation in the mrdA gene, resulting in a V522I substitution in PBP2.
No takes yet. Share an insight, caveat, or question.
McElheny et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: